Risk by age 18 years was driven by disorders within the neurodevelopmental spectrum
Protective effect suggested with female gender for schizophrenia patients with tardive dyskinesia
Patients who received 2 or 3 mg of Rexulti had significant improvements in agitation scores compared with patients taking a placebo
Solriamfetol, armodafinil-modafinil, and pitolisant reduce daytime sleepiness, with solriamfetol likely superior
Extension through Nov. 11, 2023, gives DEA and HHS a chance to consider revisions and public comments regarding proposals offered March 1
Persons receiving medication for opioid use disorder more likely to be older, White and to have public insurance
Only 26.2 percent of children with parent-reported ADHD had ever received outpatient mental health care
Proof-of-concept study is 'encouraging' for repurposing insomnia drug, authors say
Additionally, chronic disease prevalence higher in the incarcerated population
These low added therapeutic-rating drugs accounted for $19.3 billion or one-third of Medicare annual net spending in 2020